NMO Spectrum DisorderNCT05840055
ACT with NMOSD Patients and Caregivers Pilot Study
A study testing Acceptance and Commitment Therapy in people with NMO Spectrum Disorder, run by Thomas Jefferson University at 1 site in United States.
Trial summary
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their caregivers/loved ones and improving overall health outcomes in individuals with NMOSD. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- NMO Spectrum Disorder
- What is being tested?
- Acceptance and Commitment Therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2023to 21 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Individuals ages 18 and up with a diagnosis of NMOSD and caregiver loved ones willing to participate in the intervention.
- PHQ-9 score >4, or GAD-7 score >4
- Webcam access
Who cannot join
- History of suicidal attempts or acute suicidal ideation on clinical assessment
- Presence of psychotic disorder or symptoms
- Presence of psychiatric disorders that interfere with the participation of the study, judged by the study or treating clinician. The presence of other medical conditions that interfere with participation in the study, judged by the study or treating clinician
Trial locations and contacts
1 site in 1 country.
United States1 site
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19103
About this study
Official title: Acceptance and Commitment Therapy with Neuromyelitis Optica Spectrum Disorder Patient and Caregiver Pilot Study
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their caregivers/loved ones and improving overall health outcomes in individuals with NMOSD.
Read the detailed description
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is an inflammatory disorder of the central nervous system. The primary symptom of NMOSD is attacks of inflammation and damage in the optic nerves and spinal cord. Such attacks may cause rapid onset of eye pain or blindness, limb weakness, numbness, or partial paralysis, shooting pain or tingling in the neck, back or abdomen, loss of bowel and bladder control, and prolonged nausea, vomiting or hiccups. These attacks may have periods of remission and relapse, with relapses most commonly occurring years to months apart. Monophasic NMO is a less common variant of NMOSD, and is characterized by a single, severe attack that may last days or weeks. When a patient is first diagnosed with NMOSD, it is unclear whether or not they will have relapses. The psychological burden of NMOSD is documented in the empirical literature, with a focus on experience of depression, pain, sexual dysfunction, sleep issues, stigma, and impact on partners.
Between 30% and 50% of individuals with NMOSD have been found to endorse clinically significant depressive symptoms on the Beck Depression Inventory. Compared with patients with Multiple Sclerosis (MS), NMOSD patients are twice as likely to receive a formal diagnosis of Recurrent Major Depressive Disorder.
Pain, bowel and bladder dysfunction, visual impairment, reduced sexual function, and inability to work, were found to most negatively impact emotional well-being and quality of life among people with NMOSD. It is estimated that chronic pain affects over 80% of NMOSD patients, including patients without recent relapse still commonly reporting moderate or severe pain. Pain severity is the strongest negative predictor of quality of life, and the most common symptom of concern voiced by patients to their physician.
Sexual dysfunction, specifically reduced libido, decreased orgasm and erectile dysfunction have been reported by 75% of males and 75% of females living with NMOSD.
Sleep disturbance is common in NMOSD, with 64% of NMOSD patients identified as poor sleepers, with correlations with anxiety, depression, pain, disability, and disease duration. Similarly, 71.4% of NMOSD patients endorsed fatigue, with correlations with sleep disturbance, depression, pain, and quality of life.
Further contributing to the psychological burden of life with NMOSD, 60% of patients reported being affected by NMOSD-related stigma. Embarrassment due to physical limitations, perceived exclusion, avoidance/ostracism, and blame for their illness were deemed the most impactful targets of stigma.
The psychological burden is also well-defined by patients with NMOSD and their loved ones in online forums, blogs, and social media. In addition to the domains cited in the literature, patients and loved ones often discuss anxiety, delayed diagnosis, physical disability and impact on relationships as hallmark characteristics of life with NMOSD. Despite the many studies suggesting that life with NMOSD is marred by many psychological stressors, including increased depression, there does not appear to be any psychosocial intervention to date to help patients and loved ones cope with this burden. Furthermore, narratives from patients across media describe profound psychological burdens that go untreated.
Given the prevalence of depression, stress, stigma, and physical impediments associated with NMOSD, it makes sense that patients and their loved ones would resort to avoidance-based coping (distraction with television, avoiding talking about illness, avoiding reminders of illness) to manage these issues. Compared with patients with multiple sclerosis, and with healthy controls, patients with NMOSD were more likely to use mental disengagement strategies, while both NMOSD and MS patients were more likely to use acceptance and behavioral disengagement strategies, compared with healthy controls. However, while avoidance-based coping may provide an effective short-term escape from the psychological burden of NMOSD, it is considered a maladaptive coping strategy in the longer term, as avoidance can be associated with medication nonadherence, missing clinic visits, failure to inform medical providers about symptoms, and can be associated with a paradoxical increase in depression and anxiety.
While the economic burden of NMOSD, including financial cost of treatments, loss of income due to disability, and associated financial pressure on caregiver/loved ones is well known, the psychological impact of NMOSD on caregivers and loved ones remains under-studied to date. Based on PHQ-9 score, 21.1% of loved ones of NMOSD patients were found to be experiencing mild, moderate, or moderately severe depressive symptoms. However, partners did not endorse clinically significant "burden", anxiety, or depression. Rather, partners endorsed pressure to take on new roles both inside and outside of the home, during NMOSD relapses, with both male and female partners identifying challenges related to gender role shift.
Partners endorsed limiting hobbies and activities to prioritize the patient's health, particularly during a relapse, along with frustration about accommodating NMOSD symptoms in public spaces, helplessness that they cannot "fix" their partner's problems, isolation due to lack of support, and anxiety about their partner's well-being and about their own health. Male partners reported "hardly expressing thoughts and feelings about NMOSD", and reported that prior to study participation, they had "never been asked how they feel about NMOSD." Lack of caregiver support and avoidance-based coping are associated with caregiver strain and burnout. Given the physical impediments associated with NMOSD, caregivers are often responsible for managing the patient's medication regimen and transporting patients to their infusion appointments. Caregiver burnout can understandably negatively impact patient treatment engagement.
Therefore, the investigators propose a caregiver-assisted, NMOSD-specific mental health intervention. Given physical limitations associated with NMOSD, and increased comfort with telehealth over the past few years, the investigators propose a telehealth-delivered intervention will be most accessible and effective. Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a "third wave" behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis.
- Conditions
- NMO Spectrum Disorder
- Being tested
- Acceptance and Commitment Therapy
- Medical subject headings
- Neuromyelitis Optica
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acceptance and Commitment TherapyBehavioural
Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a "third wave" behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis.
| Study group | Role | What they receive |
|---|---|---|
| Acceptance and Commitment Therapy | Experimental | Not described Receives: Behavioral: Acceptance and Commitment Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Generalized Anxiety Disorder Questionnaire (GAD7)
The Generalized Anxiety Disorder Questionnaire-7 is a seven item self-report questionnaire of anxiety symptom severity, with possible scores ranging from 0-21. Higher scores indicate higher anxiety symptom severity.
Measured: Baseline, 6 weeks, and three months after study completion.
Changes in Patient Health Questionnaire (PHQ-9)
The Patient Health Questionnaire-9 is a nine item self-report questionnaire of depression symptom severity, with possible scores ranging from 0-27. Higher scores indicate higher depression symptom severity.
Measured: Baseline, 6 weeks, and three months after study completion.
Changes in Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a widely used 21-item self-report inventory used to assess anxiety levels in adults and adolescents. Scores range from 0-63, with higher scores indicating more severe anxiety.
Measured: Baseline, 6 weeks, and three months after study completion.
Changes in Beck Depression Inventory (BDI-II)
The Beck Depression Inventory is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Scores range from 0-63, with higher scores indicating more severe depression.
Measured: Baseline, 6 weeks, and three months after study completion.
Secondary outcomes (6)
Acceptance and Action Questionnaire- version 2 (AAQ-II)
The Acceptance and Action Questionnaire -version 2 is a seven-item measure of acceptance and committed action, ranging from 7-49. Higher scores indicate higher psychological inflexibility, experiential avoidance, and psychological distress. Lower total scores are associated with psychological flexibility.
Measured: Baseline, 6 weeks, and three months after study completion.
Cognitive Fusion Questionnaire - 13 item version
The Cognitive Fusion Questionnaire is a 13-item measure of cognitive fusion: rigid attachment to thoughts as truth. Total scores range from 13 - 91, with higher scores indicating a higher degree of cognitive fusion.
Measured: Baseline, 6 weeks, and three months after study completion.
Brief Fatigue Inventory
The Brief Fatigue Inventory is a 4-item measure of self-reported fatigue - Item #4 measures the extent to which fatigue has impacted each of 6 life domains. Scores range from 0-90, with higher scores indicating higher levels of fatigue and related interference.
Measured: 3 months prior to baseline to baseline, baseline to 3 months post-treatment
Telephone EDSS
The Telephone Assessment of the Expanded Disability Status Scale is a self-administered assessment of difficulty and interference of 8 neurologic categories associated with MS and NMOSD. Scores range from 0-10, with higher scores indicating higher degree of neurological symptoms and associated interference.
Measured: Baseline, 6 weeks, and three months after study completion.
Valued Living Questionnaire
The Valued Living Questionnaire is a 10-item measure of how important each of 10 valued domains are to the respondent, and to what extent the respondent has been living according to these values. Possible scores range from 10-100, with higher scores indicating higher consistency in living with one's values.
Measured: Baseline, 6 weeks, and three months after study completion.
EHR data re. NMOSD flares, hospitalization, appointments kept/missed
EHR data re. presence/absence of flares, hospitalizations, clinic visits missed/kept, infusion appts missed/delayed/kept, initiation of steroid Rx, etc.
Measured: 3 months prior to baseline to baseline, baseline to 3 months post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2023
- Study start1 Aug 2023
- Primary completion30 Sep 2024
- Study completion21 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for NMO Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by Thomas Jefferson UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thomas Jefferson University
- Sponsor type
- University, hospital or other
- Collaborators
- Alexion Pharmaceuticals, Inc.
- Responsible party
- Principal investigator, C. Virginia O'Hayer, Thomas Jefferson University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05840055
- Sponsor's protocol ID
- iRISID-2023-1442
- Status last verified
- Jan 2025
- First submitted
- 11 Apr 2023
- Last updated
- 7 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Esiason DC, Smith PJ, Peppers CL, Wakschal E, Andrews L, Nurse CN, Kushner HM, Drescher CF, Bruschwein H, Erler W, Hattrich T, Deshpande A, Levy M, Leist T, O'Hayer CV. ACT with NMOSD: A targeted, telehealth-delivered mental health intervention for patients & caregivers. Mult Scler Relat Disord. 2025 Oct;102:106630. doi: 10.1016/j.msard.2025.106630. Epub 2025 Jul 22.
PubMed 40716235
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acceptance and Commitment Therapy with Neuromyelitis Optica Spectrum Disorder Patient and Caregiver Pilot Study
- ClinicalTrials.gov ID
- NCT05840055
- Acronym / sponsor ID
- iRISID-2023-1442
- Conditions
- NMO Spectrum Disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Thomas Jefferson UniversityUniversity, hospital or other
- Collaborators
- Alexion Pharmaceuticals, Inc.
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 21 Nov 2024 (actual)
- First posted
- 3 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their caregivers/loved ones and improving overall health outcomes in individuals with NMOSD.
Detailed description
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is an inflammatory disorder of the central nervous system. The primary symptom of NMOSD is attacks of inflammation and damage in the optic nerves and spinal cord. Such attacks may cause rapid onset of eye pain or blindness, limb weakness, numbness, or partial paralysis, shooting pain or tingling in the neck, back or abdomen, loss of bowel and bladder control, and prolonged nausea, vomiting or hiccups. These attacks may have periods of remission and relapse, with relapses most commonly occurring years to months apart. Monophasic NMO is a less common variant of NMOSD, and is characterized by a single, severe attack that may last days or weeks. When a patient is first diagnosed with NMOSD, it is unclear whether or not they will have relapses. The psychological burden of NMOSD is documented in the empirical literature, with a focus on experience of depression, pain, sexual dysfunction, sleep issues, stigma, and impact on partners.
Between 30% and 50% of individuals with NMOSD have been found to endorse clinically significant depressive symptoms on the Beck Depression Inventory. Compared with patients with Multiple Sclerosis (MS), NMOSD patients are twice as likely to receive a formal diagnosis of Recurrent Major Depressive Disorder.
Pain, bowel and bladder dysfunction, visual impairment, reduced sexual function, and inability to work, were found to most negatively impact emotional well-being and quality of life among people with NMOSD. It is estimated that chronic pain affects over 80% of NMOSD patients, including patients without recent relapse still commonly reporting moderate or severe pain. Pain severity is the strongest negative predictor of quality of life, and the most common symptom of concern voiced by patients to their physician.
Sexual dysfunction, specifically reduced libido, decreased orgasm and erectile dysfunction have been reported by 75% of males and 75% of females living with NMOSD.
Sleep disturbance is common in NMOSD, with 64% of NMOSD patients identified as poor sleepers, with correlations with anxiety, depression, pain, disability, and disease duration. Similarly, 71.4% of NMOSD patients endorsed fatigue, with correlations with sleep disturbance, depression, pain, and quality of life.
Further contributing to the psychological burden of life with NMOSD, 60% of patients reported being affected by NMOSD-related stigma. Embarrassment due to physical limitations, perceived exclusion, avoidance/ostracism, and blame for their illness were deemed the most impactful targets of stigma.
The psychological burden is also well-defined by patients with NMOSD and their loved ones in online forums, blogs, and social media. In addition to the domains cited in the literature, patients and loved ones often discuss anxiety, delayed diagnosis, physical disability and impact on relationships as hallmark characteristics of life with NMOSD. Despite the many studies suggesting that life with NMOSD is marred by many psychological stressors, including increased depression, there does not appear to be any psychosocial intervention to date to help patients and loved ones cope with this burden. Furthermore, narratives from patients across media describe profound psychological burdens that go untreated.
Given the prevalence of depression, stress, stigma, and physical impediments associated with NMOSD, it makes sense that patients and their loved ones would resort to avoidance-based coping (distraction with television, avoiding talking about illness, avoiding reminders of illness) to manage these issues. Compared with patients with multiple sclerosis, and with healthy controls, patients with NMOSD were more likely to use mental disengagement strategies, while both NMOSD and MS patients were more likely to use acceptance and behavioral disengagement strategies, compared with healthy controls. However, while avoidance-based coping may provide an effective short-term escape from the psychological burden of NMOSD, it is considered a maladaptive coping strategy in the longer term, as avoidance can be associated with medication nonadherence, missing clinic visits, failure to inform medical providers about symptoms, and can be associated with a paradoxical increase in depression and anxiety.
While the economic burden of NMOSD, including financial cost of treatments, loss of income due to disability, and associated financial pressure on caregiver/loved ones is well known, the psychological impact of NMOSD on caregivers and loved ones remains under-studied to date. Based on PHQ-9 score, 21.1% of loved ones of NMOSD patients were found to be experiencing mild, moderate, or moderately severe depressive symptoms. However, partners did not endorse clinically significant "burden", anxiety, or depression. Rather, partners endorsed pressure to take on new roles both inside and outside of the home, during NMOSD relapses, with both male and female partners identifying challenges related to gender role shift.
Partners endorsed limiting hobbies and activities to prioritize the patient's health, particularly during a relapse, along with frustration about accommodating NMOSD symptoms in public spaces, helplessness that they cannot "fix" their partner's problems, isolation due to lack of support, and anxiety about their partner's well-being and about their own health. Male partners reported "hardly expressing thoughts and feelings about NMOSD", and reported that prior to study participation, they had "never been asked how they feel about NMOSD." Lack of caregiver support and avoidance-based coping are associated with caregiver strain and burnout. Given the physical impediments associated with NMOSD, caregivers are often responsible for managing the patient's medication regimen and transporting patients to their infusion appointments. Caregiver burnout can understandably negatively impact patient treatment engagement.
Therefore, the investigators propose a caregiver-assisted, NMOSD-specific mental health intervention. Given physical limitations associated with NMOSD, and increased comfort with telehealth over the past few years, the investigators propose a telehealth-delivered intervention will be most accessible and effective. Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a "third wave" behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Acceptance and Commitment Therapy | Experimental | Behavioral: Acceptance and Commitment Therapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Individuals ages 18 and up with a diagnosis of NMOSD and caregiver loved ones willing to participate in the intervention.
- PHQ-9 score >4, or GAD-7 score >4
- Webcam access
Key exclusion criteria (3 listed)
- History of suicidal attempts or acute suicidal ideation on clinical assessment
- Presence of psychotic disorder or symptoms
- Presence of psychiatric disorders that interfere with the participation of the study, judged by the study or treating clinician. The presence of other medical conditions that interfere with participation in the study, judged by the study or treating clinician
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acceptance and Commitment TherapyAcceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a "third wave" behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis. | Behavioural | Acceptance and Commitment Therapy |
Primary outcome
Changes in Generalized Anxiety Disorder Questionnaire (GAD7)
Time frame: Baseline, 6 weeks, and three months after study completion.
The Generalized Anxiety Disorder Questionnaire-7 is a seven item self-report questionnaire of anxiety symptom severity, with possible scores ranging from 0-21. Higher scores indicate higher anxiety symptom severity.
Changes in Patient Health Questionnaire (PHQ-9)
Time frame: Baseline, 6 weeks, and three months after study completion.
The Patient Health Questionnaire-9 is a nine item self-report questionnaire of depression symptom severity, with possible scores ranging from 0-27. Higher scores indicate higher depression symptom severity.
Changes in Beck Anxiety Inventory (BAI)
Time frame: Baseline, 6 weeks, and three months after study completion.
The Beck Anxiety Inventory (BAI) is a widely used 21-item self-report inventory used to assess anxiety levels in adults and adolescents. Scores range from 0-63, with higher scores indicating more severe anxiety.
Changes in Beck Depression Inventory (BDI-II)
Time frame: Baseline, 6 weeks, and three months after study completion.
The Beck Depression Inventory is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Scores range from 0-63, with higher scores indicating more severe depression.
6 secondary outcomes
Acceptance and Action Questionnaire- version 2 (AAQ-II)
Time frame: Baseline, 6 weeks, and three months after study completion.
Cognitive Fusion Questionnaire - 13 item version
Time frame: Baseline, 6 weeks, and three months after study completion.
Brief Fatigue Inventory
Time frame: 3 months prior to baseline to baseline, baseline to 3 months post-treatment
Telephone EDSS
Time frame: Baseline, 6 weeks, and three months after study completion.
Valued Living Questionnaire
Time frame: Baseline, 6 weeks, and three months after study completion.
EHR data re. NMOSD flares, hospitalization, appointments kept/missed
Time frame: 3 months prior to baseline to baseline, baseline to 3 months post-treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2025.
- Derived from this study: PubMed 40716235Esiason DC, Smith PJ, Peppers CL, Wakschal E, Andrews L, Nurse CN, Kushner HM, Drescher CF, Bruschwein H, Erler W, Hattrich T, Deshpande A, Levy M, Leist T, O'Hayer CV. ACT with NMOSD: A targeted, telehealth-delivered mental health intervention for patients & caregivers. Mult Scler Relat Disord. 2025 Oct;102:106630. doi: 10.1016/j.msard.2025.106630. Epub 2025 Jul 22.
- Individual participant dataSharing planned: No
Related trials for NMO Spectrum Disorder
RecruitingObservational study
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Not yet recruiting
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
RecruitingPhase 2
Efgartigimod for the Treatment of Acute Optic Neuritis
Optic Neuritis
RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
Active, not recruitingObservational study
Biobank For MS And Other Demyelinating Diseases
Multiple Sclerosis, Transverse Myelitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acceptance and Commitment Therapy in people with NMO Spectrum Disorder, run by Thomas Jefferson University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Generalized Anxiety Disorder Questionnaire (GAD7) (time frame: Baseline, 6 weeks, and three months after study completion.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05840055, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2025.